PDCD1 and melanoma: The results revealed that relatlimab in combination with nivolumab significantly improved progression-free survival as compared to anti-PD-1 monotherapy in patients with previously untreated metastatic or unresectable melanoma, particularly those with PD-L1 < 1% and/or LAG 3 ≥ 1%., with more clinical trials ongoing53,54.